MedTrace Logo

Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)

NCT01621386 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2017-04-20

No results posted yet for this study

Summary

This study will explore the utility of magnetic resonance imaging (MRI) to assess ventilatory defects that occur due to asthma, determine the sensitivity and specificity of MRI in response to drug treatment, and whether MRI can serve as a biomarker of treatment effects due to asthma therapy.

Conditions

Interventions

DRUG

Montelukast

Administered orally as a single daily 10 mg dose for 2 weeks

DRUG

Prednisone

Administered orally as a single daily 20 mg dose for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Cecil Charles, PhD · Duke University

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2015-09-30
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01621386 on ClinicalTrials.gov